SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is gaining traction, with community members highlighting its availability on Phantom Wallet and relative stability amidst market fluctuations. The crypto is being touted as a potential "moon" candidate, with buyers sharing enthusiasm. Conversations are centered on its performance within the Solana ecosystem.

Moo Deng

MOODENG is trending as traders discuss recent price volatility and potential for a breakout. Community members are debating entry points, with some pointing to technical analysis patterns, while others express skepticism, citing its meme coin status and past performance. The coin's listing on Robinhood and upcoming birthday are also being mentioned as potential catalysts.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following FDA approval of their leukemia drug, Revuforj, though a boxed warning regarding potentially fatal side effects tempers initial enthusiasm. The community is debating the impact of the safety label, comparing it to competitor Kura Oncology's profile, and weighing whether the market is overreacting given the drug's efficacy and the unmet need it addresses. Some believe the dip is a buying opportunity, while others worry about potential risks and side effects.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as community members discuss its potential as a Bitcoin-native meme coin, emphasizing its fair launch and strong community. Some see it as a compelling opportunity within the crypto space, drawing comparisons to other popular meme coins and highlighting its unique position on the Bitcoin network. Community members are actively sharing insights and expressing bullish sentiment, with some anticipating significant growth and exchange listings.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid discussions about a potential recall of specific lots and the impact on revenue, with community members analyzing the company's response and comparing it to similar situations with competitors. Some traders are interpreting recent stock sales by the CEO, alongside an FDA safety notice, while others suggest potential manufacturing issues. Despite concerns, many community members express confidence in the company's long-term growth and potential for a buyback.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to growing community engagement and real-world applications, with discussions focusing on its expanding ecosystem and the potential for significant growth. Community members highlight KENDU's unique approach as a permissionless brand, its active IRL presence, and the increasing number of holders. The recent release of a new website is also generating excitement, with many expressing confidence in KENDU's long-term potential.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the stock price continues to drop post FDA approval, leading to discussions around management, dilution, and future prospects. The community is debating whether the current price represents a buying opportunity or reflects deeper issues with the company's leadership and commercialization strategy. Some traders are noting potential short squeeze setups due to high short interest.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya is trending as investors discuss upcoming earnings and the company's potential for growth in the consumer credit sector, with some highlighting the AI-driven model as a key differentiator against competitors. Community members are debating the impact of recent bankruptcies of subprime lenders and analyzing insider trading activity, while also assessing the stock's valuation relative to peers like Upstart. Discussions also include speculation around potential deregulation and its impact.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending due to increasing optimism surrounding its upcoming earnings and potential undervaluation, as highlighted by a low P/E ratio. The community is actively discussing the high short interest and potential for a short squeeze, with some speculating about a possible buyout. Positive analyst ratings and strong sales growth for key products like Tavalisse are also fueling investor interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk

It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings season. Major banks exceeded expectations...

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in...

Omeros’ stock had&nbsp;its best day on Wednesday ever after H.C. Wainwright raised its price target to $20 from $9 and kept a ‘Buy’ rating, following news of a multibillion-dollar licensing deal with Novo Nordisk for its rare disease drug candidate zaltenibart.<a href="https://stocktwits.com/symbol/OMER">Shares of Omeros</a> jumped 154.1% to close at $10.42 on Wednesday, before slipping 3.1% in after-hours trading, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed shares</a> edged up 0.1% to $54.06.The brokerage said Omeros will get $240 million upfront, along with up to $510 million in development and approval milestone payments and as much as $1.3 billion tied to future sales, plus royalties. H.C. Wainwright said the new target reflects the significant non-dilutive cash Omeros will receive and updated risk assumptions for zaltenibart.Under the agreement, Novo Nordisk will take full global control of developing and commercializing zaltenibart, which targets MASP-3, a key protein linked to several rare blood and kidney disorders. The deal could be worth as much as $2.1 billion if all milestones are met. Novo Nordisk said the medicine could become a best-in-class option and will help strengthen its rare disease business.Omeros CEO Gregory Demopulos said teaming up with Novo Nordisk allows the drugmaker to expand zaltenibart’s reach worldwide while Omeros focuses on bringing its own drug, narsoplimab, to market.&nbsp;Novo Nordisk said it plans to start a global phase 3 study of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and explore its use in other rare conditions. The deal is expected to close by late 2025.On Stocktwits, retail sentiment for Omeros was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for Novo Nordisk was ‘extremely bearish’ with ‘low’ message volume.One user on Stocktwits said the royalties from the Novo Nordisk deal alone could be worth billions, adding that despite some short-seller claims, Omeros still has an impressive pipeline and plenty of funding to develop new drugs.&nbsp;<stembedurl>https://stocktwits.com/whatsgood75/message/632507728</stembedurl>Another user said they had done their own research and believe the company is waiting on FDA decisions for other promising treatments, calling Omeros a solid firm with multiple revenue streams and saying they plan to buy more shares.<stembedurl>https://stocktwits.com/SnoddyTradz/message/632496306</stembedurl>While Omeros’ stock has risen 5% so far in 202, Novo Nordisk’s U.S.-listed stock has declined 33% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Equity

Danish drugmaker Novo Nordisk (NVO) on Wednesday said that it has entered into a definitive asset purchase and license agreement with Omeros Corporation (OMER) for its drug candidate Zaltenibart.Zaltenibart is in clinical development for rare blood and kidney disorders. Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916434">deal,</a> Novo Nordisk will be granted exclusive global rights to develop and commercialize Zaltenibart in all indications.Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales. Following the closing of the transaction, Novo intends to initiate a global late-stage program for Zaltenibart in paroxysmal nocturnal hemoglobinuria, a rare, acquired blood disorder where the body's immune system mistakenly attacks and destroys red blood cells. Omeros has already reported positive mid-stage data for Zaltenibart in treating the blood disorder.The transaction is expected to close in the fourth quarter of 2025. <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> soared 136% in the pre-market session. On Stocktwits, retail sentiment around OMER jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“Novo Nordisk is in a strong position to build on the work done by Omeros to maximize the value of this asset and develop Zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders,” said Martin Holst Lange, chief scientific officer and executive vice president of Research &amp; Development at Novo Nordisk.Omeros CEO Gregory A. Demopulos said that the company will now focus on securing approval and commercialization of Narsoplimab this quarter for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Novo, meanwhile, will also explore further development of Zaltenibart in a range of other rare blood and kidney disorders.OMER stock rose 7% this year, while NVO shares dropped 34%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments.

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales.

Omeros Corporation has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).The MAA is based on response-evaluable analyses of patients treated with narsoplimab and a comparison of overall survival with a well-matched external control group.&nbsp;According to the company, the submission shows a 61% response rate and a three-fold improvement in overall survival in the narsoplimab cohort.&nbsp;It also incorporates outcomes from over 130 patients treated under Omeros’ expanded access program.Following the news, H.C. Wainwright reiterated a ‘Buy’ rating and $9 price target on the stock.&nbsp;Analyst Brandon Folkes wrote that the EMA submission supports the view that Omeros “may be entering a phase of rerating” over the next 12 months, driven by potential U.S. approval, EU approval, and renewed appreciation for the broader pipeline.&nbsp;The firm expects narsoplimab to secure regulatory clearance in both regions, creating “significant value” for the company.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Retail investors voiced concerns after Omeros Corporation’s June 27 shareholder meeting, during which audio reportedly cut out during two critical questions on the company's regulatory outlook.One user claimed that approximately 80 seconds of the meeting, covering responses to questions about the status of the biologics license application (BLA) and the FDA’s ability to meet its PDUFA timeline, were missing from both the live broadcast and its replay.&nbsp;<stembedurl>https://stocktwits.com/WinstonWolfff/message/619393411</stembedurl>“We, as shareholders, deserve to hear the complete responses,” they wrote, adding that Omeros has “a HUGE shareholder relations/communication problem.”Another investor said they emailed Omeros directly, describing the audio loss during the “most important two questions regarding FDA approval” as “beyond embarrassing.”&nbsp;<stembedurl>https://stocktwits.com/TRYII/message/619392905</stembedurl>The user called for a full update and transcript, writing: “Please do the right thing here… Many, many investors are asking and suspicious.”<a href="https://stocktwits.com/symbol/OMER">Omeros'</a> stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros first-in-class monoclonal antibody inhibiting the...

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings the Transplantation & Cellular Therapy...

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings the Transplantation & Cellular Therapy Meetings of the American Society for...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.45	--	--	N/A
Q2 '25	-$0.50	-$0.43	14.47%	BEAT
Q1 '25	-$0.57	-$0.58	-2.50%	MISSED
Q4 '24	-$0.78	-$0.54	30.37%	BEAT
Q3 '24	-$0.70	-$0.56	20.57%	BEAT

OMER
Omeros Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest OMER News

OMEROmeros Corporation